De­ci­phera re­vives hopes for Qin­lock with sub­group analy­sis, plots new PhI­II — but mar­ket re­ac­tion is mut­ed

More than a year ago, dis­ap­point­ing da­ta from a key Phase III seem­ing­ly shat­tered De­ci­phera’s hopes of mov­ing its ki­nase in­hibitor in­to ear­li­er lines of can­cer treat­ment. But now a new sub­group analy­sis may yet re­vive those hopes — al­beit in a small­er group of pa­tients.

Re­port­ing re­sults from a small ex­plorato­ry analy­sis of pa­tients with spe­cif­ic ge­net­ic mu­ta­tions, De­ci­phera said Qin­lock ap­peared to spark a ma­jor im­prove­ment in pro­gres­sion-free sur­vival as well as a promis­ing re­sponse rate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER